Cell and gene therapies
-
Experts unpack barriers to genomic future
- 17 May 2023
Five of Australia’s expert clinicians and researchers say genomics will unlock future health but Australia must first overcome these barriers.
Read more -
BioMarin’s gene therapy lands
- 26 Apr 2023
Hot on the heels of CSL’s Hemgenix, BioMarin’s first-in-class haemophilia therapy appears, along with a bispecific from Pfizer.
Read more -
Janssen’s CAR-T goes MIA
- 21 Apr 2023
Rejected by MSAC and still not TGA-approved, leaked data suggest this CAR-T may be just the game-changer clinicians proclaimed.
Read more -
Ex-Finance Mandarin to review NHRA
- 27 Feb 2023
As cell and gene therapies populate pipelines, funding of the NHRA is of increasing importance to the biopharmaceutical sector.
Read more -
MSAC to review Novartis’ Kymriah
- 24 Feb 2023
After several years of local access to the world-leading cell therapy, the committee wants to evidence that it is delivering on its promise.
Read more -
World’s most expensive drug at MSAC
- 30 Jan 2023
Application reveals the company’s funding model and pathway but at nearly $5M per dose, the gene therapy will no doubt challenge the system.
Read more -
New haem therapies offer promise
- 12 Dec 2022
Janssen, BMS, Vertex, Takeda, & CSL among the companies showing their wares at the American Society of Hematology (ASH) annual conference.
Read more -
Industry takes first step towards horizon
- 07 Dec 2022
National horizon scanning event kicks off process towards Australia’s own scanning framework.
Read more